Risk of cataract and glaucoma in patients with multiple sclerosis

Multiple Sclerosis Journal

Volumn 18, Issue 5, 2012, Pages 628-638

  Bazelier, Marloes T ^a   Mueller Schotte, Sigrid ^a,b   Leufkens, Hubert Gm ^a   Uitdehaag, Bernard Mj ^c   Van Staa, Tjeerd ^a,d,e   De Vries, Frank ^a,e,f  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF APPLIED SCIENCES UTRECHT   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d General Practice Research Database   (United Kingdom)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

cataract; epidemiology; glaucoma; glucocorticoids; multiple sclerosis

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIGLAUCOMA AGENT; CONTRACEPTIVE AGENT; ESTROGEN; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PREDNISONE;

ADULT; ARTICLE; CATARACT; CONTROLLED STUDY; FEMALE; GLAUCOMA; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; POPULATION BASED CASE CONTROL STUDY; RISK; SEX DIFFERENCE; UNITED KINGDOM;

EID: 84860466857     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511426737     Document Type: Article

References (44)

1. DuaTRomaniP. Atlas Multiple Sclerosis Resources in the World2008. http://www.who.int/mental-health/neurology/Atlas-MS-WEB.pdf (accessed 24.02.2010): World Health Organization, 2008. pp. 14.
2. Towler HM, Lightman S. Symptomatic intraocular inflammation in multiple sclerosis. Clin Experiment Ophthalmol. 2000 ; 28: 97-102
3. Donaldson MJ, Pulido JS, Herman DC, Diehl N, Hodge D. Pars planitis: a 20-year study of incidence, clinical features, and outcomes. Am J Ophthalmol. 2007 ; 144: 812-817
4. Prieto JF, Dios E, Gutierrez JM, Mayo A, Calonge M, Herreras JM. Pars planitis: epidemiology, treatment, and association with multiple sclerosis. Ocul Immunol Inflamm. 2001 ; 9: 93-102
5. James ER. The etiology of steroid cataract. J Ocul Pharmacol Ther. 2007 ; 23: 403-420
6. De Maria A, Shi Y, Kumar NM, Bassnett S. Calpain expression and activity during lens fiber cell differentiation. J Biol Chem. 2009 ; 284: 13542-13550
7. Shields DC, Schaecher KE, Saido TC, Banik NL. A putative mechanism of demyelination in multiple sclerosis by a proteolytic enzyme, calpain. Proc Natl Acad Sci U S A. 1999 ; 96: 11486-11491
8. Imam SA, Guyton MK, Haque A, Vandenbark A, Tyor WR, Ray SK, et al. Increased calpain correlates with Th1 cytokine profile in PBMCs from MS patients. J Neuroimmunol. 2007 ; 190: 139-145
9. Lowder CY, Char DH. Uveitis. A review. West J Med. 1984 ; 140: 421-432
10. Durrani OM, Tehrani NN, Marr JE, Moradi P, Stavrou P, Murray PI. Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol. 2004 ; 88: 1159-1162
11. Edelsten C, Lee V, Bentley CR, Kanski JJ, Graham EM. An evaluation of baseline risk factors predicting severity in juvenile idiopathic arthritis associated uveitis and other chronic anterior uveitis in early childhood. Br J Ophthalmol. 2002 ; 86: 51-56
12. Prieto A, Diaz D, Barcenilla H, Castrillo C, Monserrat J, Merino AG, et al. Increased spontaneous ex vivo apoptosis and subset alterations in peripheral blood T cells from patients with multiple sclerosis. J Clin Immunol. 2006 ; 26: 101-112
13. Fisher JB, Jacobs DA, Markowitz CE, Galetta SL, Volpe NJ, Nano-Schiavi ML, et al. Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology. 2006 ; 113: 324-332
14. Gugleta K, Mehling M, Kochkorov A, Grieshaber M, Katamay R, Flammer J, et al. Pattern of macular thickness changes measured by ocular coherence tomography in patients with multiple sclerosis. Klin Monbl Augenheilkd. 2008 ; 225: 408-412
15. Shindler KS, Guan Y, Ventura E, Bennett J, Rostami A. Retinal ganglion cell loss induced by acute optic neuritis in a relapsing model of multiple sclerosis. Mult Scler. 2006 ; 12: 526-532
16. Jankowska-Lech I, Terelak-Borys B, Grabska-Liberek I, Palasik W. [Glaucoma neuropathy and neuropathy in multiple sclerosis-common elements of pathogenesis?]. Klin Oczna. 2007 ; 109: 317-320
17. Chrousos GA, Kattah JC, Beck RW, Cleary PA. Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial. JAMA. 1993 ; 269: 2110-2112
18. Munjal VP, Dhir SP, Jain IS, Gangwar DN, D'Souza M. Topical corticosteroids and cataract. Ind J Ophthalmol. 1984 ; 32: 478-480
19. Kupersmith MJ, Kaufman D, Paty DW, Ebers G, McFarland H, Johnson K, et al. Megadose corticosteroids in multiple sclerosis. Neurology. 1994 ; 44: 1-4
20. Sellebjerg F, Frederiksen JL, Nielsen PM, Olesen J. Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology. 1998 ; 51: 529-534
21. de Seze J, Vukusic S, Viallet-Marcel M, Tilikete C, Zephir H, Delalande S, et al. Unusual ocular motor findings in multiple sclerosis. J Neurol Sci. 2006 ; 243: 91-95
22. Alonso A, Jick SS, Olek MJ, Hernan MA. Incidence of multiple sclerosis in the United Kingdom: findings from a population-based cohort. J Neurol. 2007 ; 254: 1736-1741
23. Ruigomez A, Garcia Rodriguez LA, Dev VJ, Arellano F, Raniwala J. Are schizophrenia or antipsychotic drugs a risk factor for cataracts?. Epidemiology. 2000 ; 11: 620-623
24. De Vries F, Bracke M, Leufkens HG, Lammers JW, Cooper C, Van Staa TP. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum. 2007 ; 56: 208-214
25. De Vries F, Pouwels S, Lammers JW, Leufkens HG, Bracke M, Cooper C, et al. Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case-control study. J Intern Med. 2007 ; 261: 170-177
26. Biswas S, Harris F, Dennison S, Singh J, Phoenix DA. Calpains: targets of cataract prevention?. Trends Mol Med. 2004 ; 10: 78-84
27. Hales AM, Chamberlain CG, Murphy CR, McAvoy JW. Estrogen protects lenses against cataract induced by transforming growth factor-beta (TGFbeta). J Exp Med. 1997 ; 185: 273-280
28. Davis VL, Chan CC, Schoen TJ, Couse JF, Chader GJ, Korach KS. An estrogen receptor repressor induces cataract formation in transgenic mice. Proc Natl Acad Sci U S A. 2002 ; 99: 9427-9432
29. Aina FO, Smeeth L, Hubbard R, Hurt LS, Fletcher AE. Hormone replacement therapy and cataract: a population-based case-control study. Eye (Lond). 2006 ; 20: 417-422
30. Bock M, Brandt AU, Dorr J, Kraft H, Weinges-Evers N, Gaede G, et al. Patterns of retinal nerve fiber layer loss in multiple sclerosis patients with or without optic neuritis and glaucoma patients. Clin Neurol Neurosurg. 2010 ; 112: 67-652
31. The Advanced Glaucoma Intervention Study (AGIS): 12. Baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucoma. Am J Ophthalmol. 2002 ; 134: 499-512
32. Czudowska MA, Ramdas WD, Wolfs RC, Hofman A, De Jong PT, Vingerling JR, et al. Incidence of glaucomatous visual field loss: a ten-year follow-up from the Rotterdam Study. Ophthalmology. 2010 ; 117: 1705-1712
33. Garbe E, LeLorier J, Boivin JF, Suissa S. Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids. Lancet. 1997 ; 350: 979-982
34. Jobling AI, Augusteyn RC. What causes steroid cataracts? A review of steroid-induced posterior subcapsular cataracts. Clin Exp Optom. 2002 ; 85: 61-75
35. Pau H. Cortical and subcapsular cataracts: significance of physical forces. Ophthalmologica. 2006 ; 220: 1-5
36. Clark AF, Wordinger RJ. The role of steroids in outflow resistance. Exp Eye Res. 2009 ; 88: 752-759
37. Goldman MJ, Schultz-Ross RA. Adverse ocular effects of anticonvulsants. Psychosomatics. 1993 ; 34: 154-158
38. Kinoshita A, Kitaoka T, Oba K, Amemiya T. Bilateral drug-induced cataract in a patient receiving anticonvulsant therapy. Jpn J Ophthalmol. 2004 ; 48: 81-82
39. Van der Most PJ, Dolga AM, Nijholt IM, Luiten PG, Eisel UL. Statins: mechanisms of neuroprotection. Prog Neurobiol. 2009 ; 88: 64-75
40. Klein BE, Klein R, Lee KE, Grady LM. Statin use and incident nuclear cataract. JAMA. 2006 ; 295: 2752-2758
41. Schlienger RG, Haefeli WE, Jick H, Meier CR. Risk of cataract in patients treated with statins. Arch Intern Med. 2001 ; 161: 2021-2026
42. Smeeth L, Hubbard R, Fletcher AE. Cataract and the use of statins: a case-control study. QJM. 2003 ; 96: 337-343
43. Smeeth L, Boulis M, Hubbard R, Fletcher AE. A population-based case-control study of cataract and inhaled corticosteroids. Br J Ophthalmol. 2003 ; 87: 1247-1251
44. Zhou Z, Althin R, Sforzolini BS, Dhawan R. Persistency and treatment failure in newly diagnosed open angle glaucoma patients in the United Kingdom. Br J Ophthalmol. 2004 ; 88: 1391-1394